Novartis AG (NVS)
| Market Cap | 189.14B |
| Revenue (ttm) | 53.00B |
| Net Income (ttm) | 24.18B |
| Shares Out | 2.23B |
| EPS (ttm) | 10.73 |
| PE Ratio | 7.91 |
| Forward PE | 13.11 |
| Dividend | $3.33 (3.92%) |
| Ex-Dividend Date | Mar 8, 2022 |
| Volume | 1,900,227 |
| Open | 83.52 |
| Previous Close | 81.86 |
| Day's Range | 83.35 - 84.83 |
| 52-Week Range | 79.09 - 95.17 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | 96.50 (+13.8%) |
| Earnings Date | Jul 19, 2022 |
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage fo... [Read more...]
Financial Performance
In 2021, Novartis AG's revenue was $52.88 billion, an increase of 5.97% compared to the previous year's $49.90 billion. Earnings were $24.02 billion, an increase of 197.58%.
Financial StatementsAnalyst Forecast
According to 35 analysts, the average rating for NVS stock is "Buy." The 12-month stock price forecast is 96.5, which is an increase of 13.76% from the latest price.
News
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leuk...
Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended grant...
Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion
Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five...
Basel, June 23, 2022 — Novartis endorses the Kigali Declaration on neglected tropical diseases (NTDs) and announces a five-year financial commitment of USD 250 million to the fight against NTDs and mala...
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
Basel, June 23, 2022 — Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of adult and ...
Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal
DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker. The post Precision BioSciences (DTIL) Stock Treks Higher on Novarti...
PerkinElmer and Novartis Collaborate to Address the Unmet Need of Sickle Cell Disease in Sub-Saharan Africa
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., a global leader committed to innovating for a healthier world, today announced that it is collaborating with Novartis, a leading global medicines compa...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
New York, New York--(Newsfile Corp. - June 15, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised t...
What Could a Recession Mean for Healthcare Stocks?
It depends on which subsector you're talking about.
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in...
Basel, June 7, 2022 — Novartis today announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (P...
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients wi...
Basel, June 6, 2022 — Novartis today announced Tafinlar® (dabrafenib) + Mekinist® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade gliom...
3 Great Dividend Stocks to Buy in June
Investors should be able to count on recurring income with these stocks.
NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encou...
NEW YORK--(BUSINESS WIRE)-- #AG--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (“Novartis” or the “Company”) (NY...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novartis AG (NVS) on Beh...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novartis AG (“Novar...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Novartis AG (NVS) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company's possible v...
The Law Offices of Frank R. Cruz Announces Investigation of Novartis AG (NVS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) on behalf of investors concerning the Company's possibl...
Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah
Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapse...
Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
Basel, May 20, 2022 — Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab)...
Three Stock Lunch: JPMorgan, Verizon and Novartis
David Wagner, Aptus Capital Advisors portfolio manager, joins 'Power Lunch' to discuss Wagner's take on stocks like JPMorgan, Verizon and Novartis.
Should You Buy This High-Yielding Big Pharma Stock?
Novartis can provide investors with a market-crushing 3.8% dividend yield -- and that isn't all the stock has to offer.
3 Undervalued Stocks to Buy Before You Sell in May and Go Away
If you really decide to sell in May and go away, you may miss out some profits from these undervalued stocks to buy. The post 3 Undervalued Stocks to Buy Before You Sell in May and Go Away appeared firs...
2 Dividend Stocks to Boost Your Passive Income
Despite challenging economic conditions, these companies are unlikely to cut their dividends.
Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
Basel, May 12, 2022 — Novartis highlights data from across its oncology portfolio at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association...